Valuation: Nanobiotix

Market Cap 1.71B 1.97B 1.59B 1.46B 2.76B 188B 2.8B 18.76B 7.36B 93.49B 7.39B 7.23B 313B P/E 2026 *
-82.1x
P/E 2027 * -142x
Enterprise Value 1.76B 2.02B 1.63B 1.5B 2.83B 193B 2.88B 19.27B 7.56B 96B 7.59B 7.42B 322B EV / Sales 2026 *
46.1x
EV / Sales 2027 * 41.7x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day-0.41%
1 week-3.77%
1 month+1.38%
3 months+17.41%
6 months+93.13%
Current year+72.92%
1 week 32.16
Extreme 32.16
36.04
1 month 30.5
Extreme 30.5
37.46
Current year 16.66
Extreme 16.66
47.66
1 year 5.66
Extreme 5.66
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap.
7/17/26 Buy

Chairman

598 0.0012%
7/17/26 Buy

Chairman

598 0.0012%
7/16/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%-3.77%+473.47%+377.62% 1.97B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.39%+0.57%+107.86%+121.19% 25.24B
Weighted average by Cap. -1.59%+1.99%+83.06%+110.85%

Financials

2026 *2027 *
Net sales 38.06M 43.78M 35.43M 32.53M 61.42M 4.18B 62.38M 418M 164M 2.08B 164M 161M 6.98B 42.83M 49.27M 39.86M 36.6M 69.11M 4.7B 70.18M 470M 184M 2.34B 185M 181M 7.85B
Net income -12.18M -14.01M -11.33M -10.41M -19.65M -1.34B -19.95M -134M -52.43M -666M -52.6M -51.45M -2.23B -52.44K -60.32K -48.81K -44.81K -84.63K -5.76M -85.94K -575K -226K -2.87M -227K -222K -9.61M
Net Debt 46M 52.92M 42.82M 39.31M 74.23M 5.05B 75.38M 505M 198M 2.51B 199M 194M 8.43B 76.4M 87.89M 71.12M 65.29M 123M 8.39B 125M 838M 329M 4.18B 330M 323M 14.01B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-07-31 €33.72 -0.41% 115,877
26-07-30 €33.86 +2.73% 79,789
26-07-29 €32.96 +0.37% 111,497
26-07-28 €32.84 -6.81% 132,268
26-07-27 €35.24 +0.57% 85,757
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.72EUR
Average target price
52.20EUR
Spread / Average Target
+54.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock